FDA Grants Orphan Drug Status to Pulmonary Arterial Hypertension Treatment
ZMA001, in development for pulmonary arterial hypertension, has been designated as an Orphan Drug by the US Food and Drug Administration.
Tag: CTEPH PAH and pulmonary hypertension
All
Latest
FDA Grants Orphan Drug Status to Pulmonary Arterial Hypertension Treatment
ZMA001, in development for pulmonary arterial hypertension, has been designated as an Orphan Drug by the US Food and Drug Administration.
Read More
Hormone Replacement Therapy May Improve Pulmonary Hypertension
Use of hormone replacement therapy (HRT) in women was associated with lower mean pulmonary artery pressure and higher right ventricular fractional shortening and right ventricular ejection fraction, according to research presented at ATS 2024.
Read More
FDA Approves Merck’s Injection for Pulmonary Arterial Hypertension
The injection on top of background therapy significantly improved exercise capacity and multiple secondary outcome measures compared to background therapy alone.
Read More
Aria CV Implants First Patient with Pulmonary Hypertension System
Aria CV Inc reports its first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System.
Read More
Cell-based Therapy Safe for Pulmonary Arterial Hypertension
Infusions of potentially therapeutic cells derived from the heart are safe for people with pulmonary arterial hypertension, according to a study led by Cedars-Sinai investigators.
Read More
Guidance for Diagnosis and Treatment of Pulmonary Hypertension Related to ILD
The Pulmonary Fibrosis Foundation and Pulmonary Hypertension Association have developed a position statement that addresses gaps in the diagnosis and treatment of patients living with pulmonary hypertension related to interstitial lung disease.
Read More
Cleveland Clinic Pulmonologist Takes Helm at Pulmonary Fibrosis FoundationÂ
The Pulmonary Fibrosis Foundation announced Franck Rahaghi, MD, MHS, FCCP, as its incoming president, CEO, and chief medical officer, effective Sept 15.
Read More
Pulmonary Rehabilitation Gets ‘Strong’ Recommendation in New ATS Guideline
The latest guideline from the American Thoracic Society reaffirms benefits for patients with COPD as well as pulmonary hypertension and interstitial lung disease.
Read More
NOxBOXi Nitric Oxide Systems Recalled
The recall was issued due to a misalignment of the check valve in the device’s manifold, which may cause the manifold to fail and interrupt therapy to neonates.
Read More
Janssen Submits New Drug Application for Investigational Single-Tablet Combo Therapy to Treat PAHÂ
The Janssen Pharmaceutical Companies of Johnson & Johnson is seeking FDA approval of an investigational single-tablet combination therapy of macitentan and tadalafil for the long-term treatment of pulmonary arterial hypertension.
Read More
Lung Care Provider Guide Available to Enhance Quality of Life for Lung Disease Patients
The new guide can assist providers in learning and practicing skills to prevent or manage respiratory symptoms in patients with chronic lung disease.
Read More
Complications for Balloon Technique for CTEPH Patients Decrease Significantly
A Michigan Medicine-led study reveals that the once-feared severe complications that occur during balloon pulmonary angioplasty have dropped in recent years.
Read More
Market Analysis: The Impact of Cylinder-free Systems on Inhaled Nitric Oxide Delivery
RT magazine spoke with manufacturers of inhaled nitric oxide delivery systems about the latest market innovations in the iNO industry, specifically about the impact of cylinder-free (“tankless”) systems, plus research on its potential use to treat other cardiopulmonary diseases.
Read More
Combo Pill for Pulmonary Hypertension Outperforms Monotherapy
The outcomes for patients with pulmonary arterial hypertension taking macitentan and tadalafil together in a single pill have been detailed in a new study, which shows significant improvement compared to those taking either drug alone.
Read More
Air Pollution Tied to Blood Pressure in Teens
Higher levels of NO2 exposure was tied with lower blood pressure, while exposure to higher levels of PM2.5 was tied to higher blood pressure.
Read More
Inhaled Nitric Oxide Delivery: Past, Present, and Future
Inhaled nitric oxide has been utilized as a pulmonary vasodilator for over 20 years and research is ongoing to uncover the usefulness of iNO in several lung diseases and disorders.Â
Read More
Pulmonary Hypertension Guidelines Call for Earlier Diagnosis
Earlier detection of pulmonary hypertension in the community and expedited referral of high-risk or complex patients are recommended in the new ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
Read More
Novel Blood Test Evaluates Pulmonary Arterial Hypertension Severity
NIH researchers have found that a novel blood test can be used to easily evaluate disease severity in patients with pulmonary arterial hypertension (PAH) and predict survivability.
Read More
Implications of Changing Pulmonary Hypertension Definitions
Experts at the World Symposium on Pulmonary Hypertension debated the definition of pulmonary hypertension.
Read More
How Does Smoking Impact High Blood Pressure Risk?
Smoking causes a temporary rise in blood pressure, but does that impact hypertension risk over the course of a lifetime?
Read More
Gene on Y Chromosome Protects Against Pulmonary Hypertension
A gene on the Y chromosome protects against pulmonary hypertension, which may partially explain why the disease occurs four times more often in women than men.
Read More
Study: Evaluating Risk Stratification in Pulmonary Arterial Hypertension
The findings of an evaluation of several risk assessment tools for pulmonary arterial hypertension were recently published in the journal Respiration.
Read More
Sleep Apnea in Pregnancy Tied to Hypertension, Metabolic Syndrome
The presence of sleep apnea measured both during pregnancy and two to seven years after delivery was associated with the development of hypertension and metabolic syndrome.
Read More
COPD Phenotyping Can Help Manage Pulmonary Hypertension
Patients with pulmonary hypertension and chronic obstructive pulmonary disease can now be identified by looking at three clinical variables, new research shows.
Read More